SAN ANTONIO, TX– Vanguard Pharmaceutical Corp. (PINKSHEETS: VGPH), a company providing the market with affordable and safe generic medicines, has signed an exclusive distribution agreement with Mac Mohan Pharma Ltd., a leading anticancer manufacturer in India. Vanguard has been granted Mac Mohan’s exclusive importer and distributor in Peru, Brazil, Paraguay, and Cameroon.
Mac Mohan’s mission is to become the number one generic oncology company in the world. It is already number one in the Philippines and is getting close in the Ukraine and Srilanka. Vanguard’s competent team will strive to capture a large market share in each country it enters and will work towards Mac Mohan’s mission.
Mac Mohan manufactures over 30 solid tumor, hematological, and supportive care products. It is redefining the pharmaceutical industry with soundly researched, effective and safe medicines to combat cancer. Mac Mohan was the first in India to launch ready to use Epirubicin Inj. and Zolendronic Acid Inj, and the second to launch room temperature stable Paclitaxel Inj and Oxaliplatin Inj. Further, an exclusive 100,000 sq ft US FDA compliant facility is to be commission by August 2009.
The anticancer product line is accepted by leading oncologists and can be found at www.vanguardpharm.com.
About Vanguard Pharmaceutical
In an era of ageing populations and rising health care costs. Vanguard’s mission is to provide the market with drugs they can afford and with an assurance of its quality. To provide the market with affordable and safe drugs, Vanguard has focused on generic medicines. Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure.
Vanguard’s main stream of business is the sale of generic drugs. It is currently targeting Latin America as it is believed to have a substantially unmet demand for advanced generics. The region is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009. Through its R&D facilities, Vanguard will strive to increase its generic product line further allowing them to penetrate Latin America and, in the future, expand into other geographic markets such as North America and Europe.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
Source: Vanguard Pharmaceutical Corp.
Popularity: 2% [?]
